Pleco Therapeutics key facts
as of Oct 2026- Developer of therapies intended to treat cancer and improve the effectiveness of existing chemotherapy.
- Pleco Therapeutics is valued at approximately $25.2M as of Oct 2026 (last reported valuation).
- It has raised $31.1M; the latest was Later Stage VC ($13.7M) in Mar 2025.
- Notable investors include Oost NL, Rijksdienst voor Ondernemend Nederland, Brabant Startup Fund, Hyloris Pharmaceuticals.
- Status: Privately Held (backing).
Pleco Therapeutics's last reported valuation, Sep 2022. Nothing priced has surfaced since.
- ·Watch Pleco Therapeutics: the Monday email on marks, rounds and moves
Pleco Therapeutics funding rounds
No funding rounds for Pleco Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pleco Therapeutics
4Pleco Therapeutics valuation
Pleco Therapeutics's last reported valuation was $25.2 million in Sep 2022. No priced round, secondary trade or fund mark has surfaced since.
Pleco Therapeutics investors
4 investors are on record for Pleco Therapeutics, including Oost NL, Rijksdienst voor Ondernemend Nederland, Brabant Startup Fund and Hyloris Pharmaceuticals.
About Pleco Therapeutics
Developer of therapies intended to treat cancer and improve the effectiveness of existing chemotherapy. The company aims to extend the life span and enhance the quality of life of patients through its novel therapies that dramatically increase the effectiveness of current cancer treatments and positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell, enabling clinicians to treat cancer and also its underlying cause.
- Sector
- Healthcare
- HQ
- Apeldoorn, Netherlands
- Founded
- 2018
- Employees
- 12
- Website
- plecotherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.